Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Phase 1 Completed 42 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors.

Timeline

Start: 2005-10
Primary completion: 2009-06
Completion: 2011-01

Publications

Results Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	35 mg/m2	Oral
Subject	Irinotecan	Small molecule	50 mg/m2	Oral
Subject	Irinotecan	Small molecule	90 mg/m2	Oral
Subject	Temozolomide	Small molecule	100 mg/m2	Oral
Subject	Temozolomide	Small molecule	150 mg/m2	Oral
Subject	Vincristine	Small molecule	1.5 mg/m2	Intravenous

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Summary

Timeline

Publications

Drugs

Indications